MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial.
January 4, 2021
Antibodies, Assay Kits, Biology Cells, cDNA, Culture Cells, Devices, DNA Templates, DNA Testing, Equipments, Exosomes, Gels, Medium & Serums, NATtrol, Panel, Particles, Pcr Kits, Peptides, Recombinant Proteins, Ria Kits, RNA, Test Kits, Vector & Virus
0 Comments
Therapy of a number of myeloma is just not healing, however focusing on CD38 improves affected person survival. To additional discover this therapeutic strategy, we investigated the security and exercise of MOR202, a novel monoclonal antibody focusing on CD38, in sufferers...